Altox

Database / Pharmaceutical impurity

Pharmaceutical impurity

Scopolamine butylbromide EP impurity G bromide salt

Scopolamine butylbromide EP impurity G bromide salt is listed in the pharmaceutical impurity collection under CAS 92714-23-3. Its represented structure has formula C21H28BrNO3 and a calculated molecular weight of 422.36 g/mol.

2D chemical structure

O O O N + B r - H H H H ( S ) ( R ) ( R ) ( S ) ( S ) ( R )

Chemical identity

Catalog name
Scopolamine butylbromide EP impurity G bromide salt
Common name
Scopolamine butylbromide EP impurity G bromide salt
Chemical name
Not available
CAS
92714-23-3
SMILES
C=C(C(=O)O[C@@H]1C[C@@H]2[C@H]3O[C@H]3[C@H](C1)[N@@+]2(C)CCCC)c1ccccc1.[Br-]
InChI
InChI=1S/C21H28NO3.BrH/c1-4-5-11-22(3)17-12-16(13-18(22)20-19(17)25-20)24-21(23)14(2)15-9-7-6-8-10-15;/h6-10,16-20H,2,4-5,11-13H2,1,3H3;1H/q+1;/p-1/t16-,17-,18+,19-,20+,22+;
InChIKey
PKUGCYLBJGJIHK-UFFRVNNBSA-M
Associated API
Scopolamine butylbromide

Record ID: A9e9db9f6a751

Computed properties

C21H28BrNO3 Molecular formula
422.363 g/molMolecular weight
421.1253 DaMonoisotopic exact mass
38.83 ŲTopological polar surface area
0.1743 Calculated LogP (Wildman–Crippen)
96.7864 cm³/molMolar refractivity (Wildman–Crippen)
3 countHydrogen-bond acceptors
0 countHydrogen-bond donors

Descriptors are calculated from the displayed SMILES. Calculated LogP is not a measured partition coefficient or a pH-specific LogD. The SMILES contains 2 disconnected components. Calculations retain all represented components.

Molecular descriptor profile

Descriptor radar

Mol. weight LogP TPSA HBA HBD Rotatable 25 50 75 100

Structural feature counts

0 2 4 6 Count H-bond acceptors H-bond donors Rotatable bonds Rings Aromatic rings Stereo centers

Element composition

Br C H N O 0 6 12 18 24 Number of atoms

Radar scale: 0–100 percentile within 25,771 distinct represented structures in this release, using the midpoint rank for ties. Larger values indicate a higher descriptor rank, not greater safety or toxicity. Element counts include hydrogen and combine isotopes under each element.

Radar values and percentile reference
DescriptorValuePercentile
Molecular weight422.36374.08
Calculated LogP (Wildman–Crippen)0.174315.58
Topological polar surface area38.8321.00
Hydrogen-bond acceptors333.13
Hydrogen-bond donors011.28
Rotatable bonds (strict)669.73

Complete molecular descriptors

PropertyCalculated valueUnit / type
Molecular formulaC21H28BrNO3dimensionless
Molecular weight422.363g/mol
Monoisotopic exact mass421.1253Da
Topological polar surface area38.83Ų
Calculated LogP (Wildman–Crippen)0.1743dimensionless
Molar refractivity (Wildman–Crippen)96.7864cm³/mol
Hydrogen-bond acceptors3count
Hydrogen-bond donors0count
Rotatable bonds (strict)6count
Heavy atoms26count
Heteroatoms5count
Rings4count
Aromatic rings1count
Aliphatic rings3count
Saturated rings3count
Aromatic heterocycles0count
Aliphatic heterocycles3count
Saturated heterocycles3count
Aromatic carbocycles1count
Aliphatic carbocycles0count
Fraction of sp³ carbon atoms0.5714fraction
Formal charge0e
Disconnected components2count
Isotopically specified atoms0count
Potential atom stereocenters6count
Unspecified atom stereocenters0count
Spiro atoms0count
Bridgehead atoms2count
Labute approximate surface area166.0696Ų
Valence electrons142count
Radical electrons0count
Bertz complexity659.0936index
Balaban J0index

Ring categories overlap and should not be summed. No toxicity result, PDE, HBEL or acceptable intake is inferred from these descriptors.

Toxicological services and resources for Scopolamine butylbromide EP impurity G bromide salt

Qualification and safety assessment of Scopolamine butylbromide EP impurity G bromide salt

Explore toxicological qualification of Scopolamine butylbromide EP impurity G bromide salt and ICH M7 mutagenic impurity assessment of Scopolamine butylbromide EP impurity G bromide salt for evaluation of this impurity in its pharmaceutical context.

Where data gaps need to be addressed, resources include read-across assessment for Scopolamine butylbromide EP impurity G bromide salt and acceptable intake and limit justification for Scopolamine butylbromide EP impurity G bromide salt. The relevant approach depends on the available evidence, exposure and duration of use.

Related Altox services and technical resources

Other catalogue designations with the same represented structure

These are separate catalogue entries; shared structure does not establish interchangeable pharmacopoeial designations.

Identity sources and calculation method

Identifiers originate from the source catalogues and available public identity records. InChI and InChIKey on this page are generated from the displayed SMILES. RDKit validation checks the molecular representation; it does not independently verify every catalogue assignment.

Discuss an assessment for Scopolamine butylbromide EP impurity G bromide salt

Explore Altox services and software through the Altox Pharma-Hub.